RESEARCH - TNF-alpha inhibitors will continue to dominate first- and second-line biologic therapy for the treatment of RA through 2011

[Guest guest]

TNF-Alpha Inhibitors Will Continue To Dominate First- And Second-Line

Biologic Therapy For The Treatment Of Rheumatoid Arthritis Through

2011

Article Date: 23 Oct 2009 - 3:00 PDT

Decision Resources, one of the world's leading research and advisory

firms focusing on pharmaceutical and healthcare issues, finds that

tumor necrosis factor (TNF)-alpha inhibitors will continue to dominate

first- and second-line biologic therapy for the treatment of

rheumatoid arthritis in the United States through 2011, but the more

established branded drugs such as, Centocor Ortho Biotech's Remicade,

Abbott's Humira and Amgen/Wyeth's Enbrel, in this class will face

competition from newer entrants. The decline in use for these

established drugs will stem from physicians increasing their use of

UCB's Cimzia and Centocor Ortho Biotech's Simponi and prescribing only

one TNF-alpha inhibitor before moving out of the drug class

completely.

**********************************************************

Read the full article here:

http://www.medicalnewstoday.com/articles/168425.php

Not an MD